{"id":994969,"date":"2020-06-11T09:03:07","date_gmt":"2020-06-11T07:03:07","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=994969"},"modified":"2020-06-11T09:03:07","modified_gmt":"2020-06-11T07:03:07","slug":"aifa-nuovo-studio-covid19-job-in-pharma","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/aifa-nuovo-studio-covid19-job-in-pharma\/","title":{"rendered":"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina"},"content":{"rendered":"<p>photo by National Cancer Institute<\/p>\n<p>&nbsp;<\/p>\n<p>L&#8217;AIFA e il Comitato etico unico nazionale hanno autorizzato lo studio prospettico, interventistico IVIG\/H\/Covid-19.<\/p>\n<p>Obiettivo dello studio \u00e8 valutare l\u2019effetto del trattamento con immunoglobuline umane polivalenti somministrate ad alte dosi (IVIG) + eparina a basso peso molecolare (LMWH) in una popolazione di pazienti affetti da COVID-19, ospedalizzati, in una fase precoce della malattia che mostrano la progressione di segni di infiammazione.<\/p>\n<p>Lo studio, multicentrico, \u00e8 coordinato dall\u2019 AUO Policlinico Umberto I Roma &#8211; Centro di Riferimento per le Immunodeficienze primitive.<\/p>\n<p><a href=\"https:\/\/www.aifa.gov.it\/documents\/20142\/1178302\/IVIG-H-Covid-19_documenti.zip?download=true\">Qui<\/a> \u00e8 possibile visionare i documenti ufficiali dal sito AIFA relativi allo studio sopra, mentre in <a href=\"https:\/\/www.aifa.gov.it\/sperimentazioni-cliniche-covid-19\">questa sezione <\/a>sono disponibili le informazioni aggiornate sulle sperimentazioni in corso e i relativi documenti. Gli studi sono presentati da Aifa in ordine di approvazione (dal pi\u00f9 recente), con l&#8217;indicazione del titolo dello studio e del promotore. Per ogni sperimentazione \u00e8 possibile visualizzare\u00a0 e scaricare i documenti disponibili sempre aggiornati (protocollo, sinossi, parere del Comitato Etico, ecc.).<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>photo by National Cancer Institute &nbsp; L&#8217;AIFA e il Comitato etico unico nazionale hanno autorizzato lo studio prospettico, interventistico IVIG\/H\/Covid-19. Obiettivo dello studio \u00e8 valutare l\u2019effetto del trattamento con immunoglobuline umane polivalenti somministrate ad alte dosi (IVIG) + eparina a basso peso molecolare (LMWH) in una popolazione di pazienti affetti da COVID-19, ospedalizzati, in una fase precoce della malattia che mostrano la progressione di segni di infiammazione. Lo studio, multicentrico, \u00e8 coordinato dall\u2019 AUO Policlinico Umberto I Roma &#8211; Centro&#8230;<\/p>\n","protected":false},"author":297440,"featured_media":994970,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[2610,2771],"class_list":["post-994969","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-aifa","tag-studio-clinico"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by National Cancer Institute &nbsp; L&#8217;AIFA e il Comitato etico unico nazionale hanno autorizzato lo studio prospettico, interventistico IVIG\/H\/Covid-19. Obiettivo dello studio \u00e8 valutare l\u2019effetto del trattamento con immunoglobuline umane polivalenti somministrate ad alte dosi (IVIG) + eparina a basso peso molecolare (LMWH) in una popolazione di pazienti affetti da COVID-19, ospedalizzati, in una fase precoce della malattia che mostrano la progressione di segni di infiammazione. Lo studio, multicentrico, \u00e8 coordinato dall\u2019 AUO Policlinico Umberto I Roma &#8211; Centro...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-11T07:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/06\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina\",\"datePublished\":\"2020-06-11T07:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/\"},\"wordCount\":170,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg\",\"keywords\":[\"AIFA\",\"studio clinico\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/\",\"name\":\"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg\",\"datePublished\":\"2020-06-11T07:03:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"National Cancer Institute\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/aifa-nuovo-studio-covid19-job-in-pharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina - Frezza Partners","og_description":"photo by National Cancer Institute &nbsp; L&#8217;AIFA e il Comitato etico unico nazionale hanno autorizzato lo studio prospettico, interventistico IVIG\/H\/Covid-19. Obiettivo dello studio \u00e8 valutare l\u2019effetto del trattamento con immunoglobuline umane polivalenti somministrate ad alte dosi (IVIG) + eparina a basso peso molecolare (LMWH) in una popolazione di pazienti affetti da COVID-19, ospedalizzati, in una fase precoce della malattia che mostrano la progressione di segni di infiammazione. Lo studio, multicentrico, \u00e8 coordinato dall\u2019 AUO Policlinico Umberto I Roma &#8211; Centro...","og_url":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/","og_site_name":"Frezza Partners","article_published_time":"2020-06-11T07:03:07+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/06\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina","datePublished":"2020-06-11T07:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/"},"wordCount":170,"image":{"@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/06\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg","keywords":["AIFA","studio clinico"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/","url":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/","name":"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/06\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg","datePublished":"2020-06-11T07:03:07+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/06\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/06\/national-cancer-institute-1fvqUP-xaYQ-unsplash-scaled.jpg","width":2560,"height":1707,"caption":"National Cancer Institute"},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/aifa-nuovo-studio-covid19-job-in-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Covid-19, Aifa autorizza studio sugli effetti di immunoglobuline ed eparina"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/994969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=994969"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/994969\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/994970"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=994969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=994969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=994969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}